» Articles » PMID: 39085703

Decoding High Mobility Group A2 Protein Expression Regulation and Implications in Human Cancers

Overview
Journal Discov Oncol
Publisher Springer
Specialty Oncology
Date 2024 Jul 31
PMID 39085703
Authors
Affiliations
Soon will be listed here.
Abstract

High Mobility Group A2 (HMGA2) oncofetal proteins are a distinct category of Transcription Factors (TFs) known as "architectural factors" due to their lack of direct transcriptional activity. Instead, they modulate the three-dimensional structure of chromatin by binding to AT-rich regions in the minor grooves of DNA through their AT-hooks. This binding allows HMGA2 to interact with other proteins and different regions of DNA, thereby regulating the expression of numerous genes involved in carcinogenesis. Consequently, multiple mechanisms exist to finely control HMGA2 protein expression at various transcriptional levels, ensuring precise concentration adjustments to maintain cellular homeostasis. During embryonic development, HMGA2 protein is highly expressed but becomes absent in adult tissues. However, recent studies have revealed its re-elevation in various cancer types. Extensive research has demonstrated the involvement of HMGA2 protein in carcinogenesis at multiple levels. It intervenes in crucial processes such as cell cycle regulation, apoptosis, angiogenesis, epithelial-to-mesenchymal transition, cancer cell stemness, and DNA damage repair mechanisms, ultimately promoting cancer cell survival. This comprehensive review provides insights into the HMGA2 protein, spanning from the genetic regulation to functional protein behavior. It highlights the significant mechanisms governing HMGA2 gene expression and elucidates the molecular roles of HMGA2 in the carcinogenesis process.

Citing Articles

Impact of C-FOS/C-JUN Transcriptional Factors Co-Expression in Non-small Cell Lung Carcinoma.

Manios K, Chrysovergis A, Papanikolaou V, Tsiambas E, Adamopoulou M, Stamatelopoulos A Cancer Diagn Progn. 2025; 5(1):15-20.

PMID: 39758236 PMC: 11696338. DOI: 10.21873/cdp.10406.


HMGA2 overexpression with specific chromosomal abnormalities predominate in CALR and ASXL1 mutated myelofibrosis.

Handa S, Schaniel C, Tripodi J, Ahire D, Mia M, Klingborg S Leukemia. 2024; 39(3):663-674.

PMID: 39715853 PMC: 11879852. DOI: 10.1038/s41375-024-02496-0.

References
1.
Hauke S, Rippe V, Bullerdiek J . Chromosomal rearrangements leading to abnormal splicing within intron 4 of HMGIC?. Genes Chromosomes Cancer. 2001; 30(3):302-4. View

2.
Wang T, Wang G, Hao D, Liu X, Wang D, Ning N . Aberrant regulation of the LIN28A/LIN28B and let-7 loop in human malignant tumors and its effects on the hallmarks of cancer. Mol Cancer. 2015; 14:125. PMC: 4512107. DOI: 10.1186/s12943-015-0402-5. View

3.
Gaudreau-LaPierre A, Klonisch T, Nicolas H, Thanasupawat T, Trinkle-Mulcahy L, Hombach-Klonisch S . Nuclear High Mobility Group A2 (HMGA2) Interactome Revealed by Biotin Proximity Labeling. Int J Mol Sci. 2023; 24(4). PMC: 9966875. DOI: 10.3390/ijms24044246. View

4.
Jin L, Lloyd R, Nassar A, Lappinga P, Sebo T, Swartz K . HMGA2 expression analysis in cytological and paraffin-embedded tissue specimens of thyroid tumors by relative quantitative RT-PCR. Diagn Mol Pathol. 2011; 20(2):71-80. DOI: 10.1097/PDM.0b013e3181ed784d. View

5.
Vignali R, Marracci S . HMGA Genes and Proteins in Development and Evolution. Int J Mol Sci. 2020; 21(2). PMC: 7013770. DOI: 10.3390/ijms21020654. View